bevacizumab,atezolizumab,cisplatin,pembrolizumab
roche,merck
['gism', '#gi', 'atezo', ' bev ', 'imbrave050', 'hcc']
4. #imbrave050: localized hcc s/p ablation/resection, followed by surveillance vs adj atezolizumab + bev - met primary endpoint: 12 mos irf-rfs (hr 0.72, p=0.012)
- comparable health related qol #asco23 #gism 5/7 
Practice changing 🗣 for community oncologists: w/ Rohit Gosain @UPMCHillmanCC & Rahul Gosain @WilmotCancer. Views are our own. COI: https://t.co/cJOjp0RvQE